Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06389955 · ClinicalTrials.gov registry record · Phase 1
Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT06389955 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 12 participants.
The verdict
NCT06389955, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study comprised of 2 parts, Part A and Part B. Part B will only be conducted if the relative bioavailability of the tablet formulation was at least 70% of the capsule formulation.
Interventions
- DRUG TP 3654
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2023-08-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06389955
The ClinicalTrials.gov registry entry for NCT06389955 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TP 3654 is the first listed.
NCT06389955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06389955 about?
NCT06389955 is a clinical study titled "Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654". This study comprised of 2 parts, Part A and Part B. Part B will only be conducted if the relative bioavailability of the tablet formulation was at least 70% of the capsule formulation.
What is the current status of trial NCT06389955?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-05-22. Estimated completion is 2023-08-24.
What interventions are being tested in trial NCT06389955?
The interventions under investigation include: TP 3654 (DRUG).
Who is sponsoring clinical trial NCT06389955?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.